Vasopressin V1 receptor-mediated aldosterone production as a result of selective V2 receptor antagonism: A potential explanation for the failure of tolvaptan to reduce cardiovascular outcomes in the EVEREST trial

Bertram Pitt; Mihai Gheorghiade

doi:10.1093/eurjhf/hfr150

Vasopressin V1 receptor-mediated aldosterone production as a result of selective V2 receptor antagonism: A potential explanation for the failure of tolvaptan to reduce cardiovascular outcomes in the EVEREST trial

Bertram Pitt^*, Mihai Gheorghiade

^*Corresponding author for this work

Medicine, Cardiology Division

Research output: Contribution to journal › Editorial

8 Scopus citations

Original language	English (US)
Pages (from-to)	1261-1263
Number of pages	3
Journal	European Journal of Heart Failure
Volume	13
Issue number	12
DOIs	https://doi.org/10.1093/eurjhf/hfr150
State	Published - Dec 2011

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1093/eurjhf/hfr150

Cite this

Pitt, B., & Gheorghiade, M. (2011). Vasopressin V1 receptor-mediated aldosterone production as a result of selective V2 receptor antagonism: A potential explanation for the failure of tolvaptan to reduce cardiovascular outcomes in the EVEREST trial. European Journal of Heart Failure, 13(12), 1261-1263. https://doi.org/10.1093/eurjhf/hfr150

@article{e49cc7bbb6eb49739aa026523c80ac81,

title = "Vasopressin V1 receptor-mediated aldosterone production as a result of selective V2 receptor antagonism: A potential explanation for the failure of tolvaptan to reduce cardiovascular outcomes in the EVEREST trial",

author = "Bertram Pitt and Mihai Gheorghiade",

year = "2011",

month = dec,

doi = "10.1093/eurjhf/hfr150",

language = "English (US)",

volume = "13",

pages = "1261--1263",

journal = "European Journal of Heart Failure",

issn = "1388-9842",

publisher = "Oxford University Press",

number = "12",

}

Vasopressin V1 receptor-mediated aldosterone production as a result of selective V2 receptor antagonism : A potential explanation for the failure of tolvaptan to reduce cardiovascular outcomes in the EVEREST trial. / Pitt, Bertram; Gheorghiade, Mihai.

In: European Journal of Heart Failure, Vol. 13, No. 12, 12.2011, p. 1261-1263.

Research output: Contribution to journal › Editorial

TY - JOUR

T1 - Vasopressin V1 receptor-mediated aldosterone production as a result of selective V2 receptor antagonism

T2 - A potential explanation for the failure of tolvaptan to reduce cardiovascular outcomes in the EVEREST trial

AU - Pitt, Bertram

AU - Gheorghiade, Mihai

PY - 2011/12

Y1 - 2011/12

UR - http://www.scopus.com/inward/record.url?scp=81855194762&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=81855194762&partnerID=8YFLogxK

U2 - 10.1093/eurjhf/hfr150

DO - 10.1093/eurjhf/hfr150

M3 - Editorial

C2 - 22102625

AN - SCOPUS:81855194762

VL - 13

SP - 1261

EP - 1263

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

SN - 1388-9842

IS - 12

ER -